Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma
Modern Pathology · 2024
DOI: 10.1016/j.modpat.2024.100516 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Modern Pathology, 2024. Verfasst von Ismael Fernández-Miranda und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Lymphoma Research Group, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, Madrid, Spain. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Nomograms, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Follicular lymphoma (FL) is the most frequent indolent lymphoma. Some patients (10%-15%) experience histologic transformation (HT) to a more aggressive lymphoma, usually diffuse large B-cell lymphoma (DLBCL). This study aimed to validate and improve a genetic risk model to predict HT at diagnosis.We collected mutational data from diagnosis biopsies of 64 FL patients. We combined them with the data from a previously published cohort (total n = 104; 62 from nontransformed and 42 from patients who did transform to DLBCL). This combined cohort was used to develop a nomogram to estimate the risk of HT. Prognostic mutated genes and clinical variables were assessed using Cox regression analysis to generate a risk model. The model was internally validated by bootstrapping and externally validated in an independent cohort. Its performance was evaluated using a concordance index and a calibration curve. The clinicogenetic nomogram included the mutational status of 3 genes (HIST1HE1, KMT2D, and TNFSR14) and high-risk Follicular Lymphoma International Prognostic Index and predicted HT with a concordance index of 0.746. Patients were classified as being at low or high risk of transformation. The probability HT function at 24 months was 0.90 in the low-risk group vs 0.51 in the high-risk group and, at 60 months, 0.71 vs 0.15, respectively. In the external validation cohort, the probability HT function in the low-risk group was 0.86 vs 0.54 in the high-risk group at 24 months, and 0.71 vs 0.32 at 60 months. The concordance index in the external cohort was 0.552. In conclusion, we propose a clinicogenetic risk model to predict FL HT to DLBLC, combining genetic alterations in HIST1H1E, KMT2D, and TNFRSF14 genes and clinical features (Follicular Lymphoma International Prognostic Index) at diagnosis. This model could improve the management of FL patients and allow treatment strategies that would prevent or delay transformation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Lymphoma Research Group, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, Madrid, Spain.
- Department of Medical Oncology, Lymphoma Research Group, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, Madrid, Spain; CoE Data Intelligence, Fujitsu Technology Solutions S.A., Pozuelo de Alarcón, Madrid…
- Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Department of Pathology, Hospital del Mar, Barcelona, Spain.
- Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain.
- Department of Pathology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.
- Biostatistics Unit, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA. CIBERESP, ISCIII. Madrid, Spain.
Zitieren
APA
Fernández-Miranda, I., Pedrosa, L., González-Rincón, J., Espinet, B., de la Cruz Vicente, F., Climent, F., Gómez, S., Royuela, A., Camacho, F. I., Martín-Acosta, P., Yanguas-Casás, N., Domínguez, M., Méndez, M., Colomo, L., Salar, A., Horcajo, B., Navarro, M., García-Cosío, M., Piris-Villaespesa, M., …, & Sánchez-Beato, M. (2024). Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100516
Vancouver
Fernández-Miranda I, Pedrosa L, González-Rincón J, Espinet B, de la Cruz Vicente F, Climent F, et al. Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100516
BibTeX
@article{FernndezMiranda2024,
author = {Fernández-Miranda, Ismael and Pedrosa, Lucía and González-Rincón, Julia and Espinet, Blanca and de la Cruz Vicente, Fátima and Climent, Fina and Gómez, Sagrario and Royuela, Ana and Camacho, Francisca I and Martín-Acosta, Paloma and Yanguas-Casás, Natalia and Domínguez, Marina and Méndez, Miriam and Colomo, Luis and Salar, Antonio and Horcajo, Beatriz and Navarro, Marta and García-Cosío, Mónica and Piris-Villaespesa, Miguel and Llanos, Marta and García, Juan F and Sequero, Silvia and Mercadal, Santiago and García-Hernández, Sonia and Navarro, Belén and Mollejo, Manuela and Provencio, Mariano and Sánchez-Beato, Margarita},
title = {Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma},
journal = {Modern Pathology},
year = {2024},
doi = {10.1016/j.modpat.2024.100516}
}
EUVIMED